---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-003763"
form_type: "8-K"
ticker: "INBP"
cik: "0001016504"
company_name: "INTEGRATED BIOPHARMA INC"
filed_at: "2024-02-12T23:59:59+00:00"
generated_at: "2026-06-06T04:04:48.589866+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Integrated BioPharma Q2 revenue down 6.5% to $11.5M; net loss widens to $0.4M

## Summary
- Revenue $11.5M vs $12.3M in prior-year quarter (-6.5%).
- Operating loss of ~$0.5M vs ~$33K loss a year ago.
- Net loss of $0.4M ($0.01 per share) vs $3K loss ($0.00) prior year.
- Six-month revenue $24.4M vs $24.6M; net loss $0.4M vs $0.1M.
- Two largest customers represent ~90% of total revenue; company aims to diversify by FY2025.

## SEC filing metadata
- accession: 0001437749-24-003763
- form_type: 8-K
- ticker: INBP
- cik: 0001016504
- company_name: INTEGRATED BIOPHARMA INC
- filed_at: 2024-02-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1016504/000143774924003763/0001437749-24-003763-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1016504/000143774924003763/inbp20240209_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-003763
- JSON: https://secwatch.observer/filing/0001437749-24-003763.json
- Plain text: https://secwatch.observer/filing/0001437749-24-003763.txt

## Key facts
- Earnings Releases
  INTEGRATED BIOPHARMA INC reported the quarter ended December 31, 2023 results: revenue $11.5 million, net income net loss of approximately $0.4 million, EPS $0.01.
  - Period: the quarter ended December 31, 2023
  - Revenue: $11.5 million
  - Net income: net loss of approximately $0.4 million
  - EPS: $0.01
  - Result: reported results
  source text: Inc. ((OTCQX: INBP)) (the “Company” or “INBP”) reports its financial results for the quarter ended December 31, 2023. Revenue for the quarter ended December 31, 2023 was $11.5 million compared to $12.3 million for the quarter ended December 31, 2022, a decrease of $0.8 million or 6.5%. The Company had operating losses for the quarters ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1016504/000143774924003763/0001437749-24-003763-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.